Search results for "transitional"

showing 10 items of 125 documents

VALUTAZIONE CLINICA DELLA PROTEINA 22 DELLA MATRICE NUCLEARE COME MARCATORE TUMORALE NEL FOLLOW-UP DEI TUMORI A CELLULE TRANSIZIONALI DELLA VESCICA

2008

OBJECTIVES. Biomarkers (BTA, NMP22, FDP etc.) have been and continue to be evaluated as adjuncts or substitutes for cystoscopy, which is invasive and uncomfortable for some patients. Nuclear matrix protein-22 (NMP22) is involved in the regulation of nuclear processes. The main objective of the present study is to evaluate the clinical utility of urinary NMP22 as a tumor marker in the follow-up of transitional cell carcinoma (TCC) of the bladder. MATERIALS AND METHODS. The study included 62 patients undergoing follow-up, who had had TCC of bladder but who were disease-free at the beginning of the study, as confirmed by cystoscopy. Urine samples were collected for urinary cytology and NMP22 t…

NMP22 BIOMARKERS TRANSITIONAL CELL CARCINOMA OF THE BLADDERSettore MED/24 - Urologia
researchProduct

Intravesical bleomycin in bladder tumour prophylaxis.

1986

The authors have evaluated the efficacy, tolerability and systemic absorption of bleomycin administered by intravesical route in the prophylaxis of recurrences of superficial vesical tumours after endoscopic resection (TUR). Thirty mg of bleomycin dissolved in 30 ml of saline solution were instilled in the bladder once a week for the first month and then once a month for 12 months. The instilled fluid was held in the bladder for 1 hour. The systemic absorption of the drug was evaluated by a microbiological assay of bleomycin in plasma and in the perfusion liquid recovered from the bladder. Fifteen patients were treated; most had a long history of multiple recurrent tumours despite previous …

NephrologyMalemedicine.medical_specialtyContact timeUrologymedicine.medical_treatmentBleomycinchemistry.chemical_compoundBleomycinInternal medicinemedicineIntravesical routeHumansSalineAgedCarcinoma Transitional Cellbusiness.industryMiddle AgedSurgeryTolerabilitychemistryUrinary Bladder NeoplasmsNephrologyToxicityFemaleNeoplasm Recurrence LocalbusinessPerfusionInternational urology and nephrology
researchProduct

The pathologist's role in the detection of rare variants of bladder cancer and analysis of the impact on incidence and type detection.

2018

BACKGROUND: Histology is one of the most important factors determining the prognosis of bladder cancers and rare variants are generally associated with decreased disease specific survival compared to pure transitional cell carcinomas. We believe that rare bladder cancer variants are likely underdiagnosed in the absence of a dedicated uro-pathologist in many centers. The objective of this study is to evaluate the contribution of a dedicated uro-pathologist on the identification of rare bladder cancer variants. METHODS: We retrospectively analyzed the clinical and histological records of all patients which underwent a radical cystectomy and lymph node dissection between January 2000 and Septe…

NephrologyMalemedicine.medical_specialtyPathologymedicine.medical_treatmentConcordanceUrology030232 urology & nephrologyCystectomyCystectomy03 medical and health sciences0302 clinical medicineProfessional RoleInternal medicineUrinary bladder neoplasmCarcinomaMedicineHumansCarcinoma transitional cell; Cystectomy; Urinary bladder neoplasms; Aged; Carcinoma Transitional Cell; Cystectomy; Female; Humans; Incidence; Lymph Node Excision; Male; Middle Aged; Professional Role; Retrospective Studies; Urinary Bladder Neoplasms; Pathologists; Nephrology; UrologyLymph nodeAgedRetrospective StudiesCarcinoma Transitional CellBladder cancerbusiness.industryIncidenceCarcinomaRetrospective cohort studyMiddle Agedmedicine.diseasePathologistsDissectionmedicine.anatomical_structureUrinary Bladder NeoplasmsNephrology030220 oncology & carcinogenesistransitional cellLymph Node ExcisionFemalebusinessMinerva urologica e nefrologica = The Italian journal of urology and nephrology
researchProduct

Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy

2018

PURPOSE: To evaluate the oncological impact of postponing radical cystectomy (RC) to allow further conservative therapies prior to progression in a large multicentre retrospective cohort of T1-HG/G3 patients initially treated with BCG. METHODS: According to the time of RC, the population was divided into 3 groups: patients who did not progress to muscle-invasive disease, patients who progressed before radical cystectomy and patients who experienced progression at the time of radical cystectomy. Clinical and pathological outcomes were compared across the three groups. RESULTS: Of 2451 patients, 509 (20.8%) underwent RC. Patients with tumors > 3 cm or with CIS had earlier cystectomies (HR = 1…

NephrologyMalemedicine.medical_treatment030232 urology & nephrologyKaplan-Meier EstimateSettore MED/24 - UrologiaCohort Studies0302 clinical medicineRetrospective StudieMultivariate AnalysiOutcomeeducation.field_of_studyHigh riskBladder cancerMiddle AgedPrognosisEditorialTreatment OutcomeLocal030220 oncology & carcinogenesisBCG VaccineFemaleSurvival AnalysiBladder cancer; Cystectomy; Extravesical disease; High risk; Outcomes; T1G3; UrologyHumanmedicine.medical_specialtyPrognosiUrologyPopulationUrologyOutcomesT1G3CystectomyRisk AssessmentDisease-Free SurvivalCystectomy03 medical and health sciencesAll institutes and research themes of the Radboud University Medical CenterInternal medicineUrological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]medicineHumansNeoplasm InvasivenesseducationSurvival analysisProportional Hazards ModelsRetrospective StudiesAgedNeoplasm StagingNeoplasm InvasiveneCarcinoma Transitional CellBladder cancerbusiness.industryProportional hazards modelBladder cancer; Cystectomy; Extravesical disease; High risk; Outcomes; T1G3; Aged; BCG Vaccine; Carcinoma Transitional Cell; Cohort Studies; Cystectomy; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Recurrence Local; Neoplasm Staging; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Survival Analysis; Treatment Outcome; Urinary Bladder NeoplasmsCarcinomaRetrospective cohort studymedicine.diseaseSurvival AnalysisNeoplasm RecurrenceUrinary Bladder NeoplasmsConcomitantMultivariate AnalysisProportional Hazards ModelTransitional CellCohort StudieNeoplasm Recurrence LocalbusinessExtravesical disease
researchProduct

ABH-antigenicity of transitional cell carcinoma of the urinary bladder in patients subjected to topical chemoprophylaxis

1983

Topical chemoprophylaxis with adriamycin was administered to 49 patients with UICC-stages pTA and PT1 (pathological stage 0 and A) of transitional cell carcinoma of the urinary bladder. Tumor specimens obtained prior to initiation of the instillation protocol were evaluated with regard to ABH-antigenicity. ABH-antigens were present in tumors of 19 patients and none of these developed muscle-infiltrating recurrences during or after intravesical chemoprophylaxis. The primary lesions of 30 patients were deleted of antigens; only 5 (16%) developed a progressive recurrence. Compared to a historical control group this is thought to be a true reduction of invasive tumor recurrences in ABH-negative…

Nephrologymedicine.medical_specialtyAntigenicityUrinary bladderbusiness.industryUrologyUrologymedicine.diseasemedicine.anatomical_structureTransitional cell carcinomaAntigenInternal medicineChemoprophylaxismedicineStage (cooking)businessPathologicalWorld Journal of Urology
researchProduct

Regional specificities in the distribution, chemical phenotypes, and coexistence patterns of neuropeptide containing nerve fibres in the human anal c…

1993

Despite the pivotal clinical significance of the human anal canal, little is known about its total and specific innervation. This study assessed the comparative distribution and histotopology of nerve fibres immunoreactive for neural markers and a variety of regulatory active neuropeptides in the human anal canal by light microscopic immunohistochemistry. Depending on the epithelial zone and region of the anal canal, the neural elements were differentially immunoreactive for the pan-neural marker protein gene product 9.5, the catecholamine marker tyrosine hydroxylase, the neuroendocrine marker chromogranin A, and various neuropeptides. Protein gene product 9.5-immunoreactive nerve fibres we…

Nervous systemPathologymedicine.medical_specialtyGeneral NeuroscienceRectumChromogranin ANerve fiberAnatomyBiologyAnal canalEpitheliummedicine.anatomical_structureDermismedicinebiology.proteinAnal Transitional ZoneJournal of Comparative Neurology
researchProduct

The spread of the Atlantic blue crab Callinectes sapidus Rathbun 1896 in the Mediterranean Sea: analysis of environmental and trophic niche and metal…

2023

Biological invasions are globally acknowledged as one of the major causes of biodiversity loss. Considering the urgency of understanding what are the effects of biological invasions on recipient ecosystems, this research focuses on the Atlantic blue crab Callinectes sapidus, one of the most successful invaders of Mediterranean coastal ecosystems. First, a general assessment of the overlap of the Grinnellian niche of the species in native and invaded ranges was carried out to verify whether the blue crab maintained the characteristics of its climatic niche when establishing in invaded areas (niche conservatism hypothesis) or, alternatively, it adapted to the specific abiotic characteristics …

Non-indigenous specieTransitional ecosystemStagnone di MarsalaPopulation dynamic.Invasive specieMarine coastal areaStable isotopeAlien specie
researchProduct

Re: The Role of Squamous Differentiation in Patients with Transitional Cell Carcinoma of the Bladder Treated with Radical Cystectomy

2008

OncologyCystectomymedicine.medical_specialtyTransitional cell carcinomabusiness.industryUrologySquamous Differentiationmedicine.medical_treatmentInternal medicinemedicineIn patientbusinessmedicine.diseaseEuropean Urology
researchProduct

Metastatic pattern of breast cancer according to immunohistochemical defined subtypes in the transitional phase of adjuvant trastuzumab treatment.

2014

e11581 Background: Prognosis of early breast cancer (BC) differs significantly upon subtypes (ST). Treatment with adjuvant trastuzumab improves outcome of HER2 overexpressing BC, however, less in k...

OncologyGynecologyCancer Researchmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentmedicine.diseaseTransitional phaseBreast cancerOncologyTrastuzumabInternal medicineMedicineImmunohistochemistryskin and connective tissue diseasesbusinessneoplasmsAdjuvantmedicine.drugEarly breast cancerJournal of Clinical Oncology
researchProduct

Combination of intravesical chemotherapy and hyperthermia for the treatment of superficial bladder cancer: preliminary clinical experience

2003

The prevalence of superficial transitional cell carcinoma of the bladder (STCCB) is still increasing in spite of improved adjuvant chemotherapic and/or immunoprophylaxis approaches. Thus, there is certainly an urgent need to improve our ability to control this disease. Local hyperthermia has a therapeutical potential for the treatment of many solid tumors, especially when used in combination with other treatments, such as radiation and chemotherapy. In particular, a synergistic or, at least, supra-additive antitumor cell killing effect was documented when local hyperthermia was administered in combination with selected cytostatic drugs. Recently, advances in miniaturized technology have all…

OncologyHyperthermiamedicine.medical_specialtymedicine.medical_treatmentAntineoplastic AgentsInternal medicinemedicineAnimalsHumansChemotherapyBladder cancerUrinary bladderbusiness.industryHyperthermia InducedHematologymedicine.diseaseCombined Modality TherapySurgeryRegimenAdministration IntravesicalTreatment OutcomeCell killingTransitional cell carcinomamedicine.anatomical_structureUrinary Bladder NeoplasmsOncologyintravesical chemotherapy hyperthermia bladder cancerNeoplasm Recurrence LocalbusinessAdjuvantCritical Reviews in Oncology/Hematology
researchProduct